Disorders of iron metabolism are commonly seen in onco-hematological clinical practice. Iron-deficiency anemia and cancer-associated anemia are usually treated with supportive therapies. Optimal management of these conditions are discussed in this perspective paper. Areas covered: A position paper discussing a number of hot topics on anemia in cancer patients is presented. The main areas covered by experts in the field are: definitions, prevalence and consequences of anemia and iron deficiency, incidence of anemia resulting from targeted therapies, importance of anemia diagnosis and monitoring, evaluation of iron status before and during treatment, role of transfusions and erythropoiesis-stimulating agents, management of iron deficiency wit...
Unresponsiveness to erythropoiesis-stimulatory agents (ESA), which occurs in 30% to 50% of patients,...
Unresponsiveness to erythropoiesis-stimulatory agents (ESA), which occurs in 30% to 50% of patients,...
Unresponsiveness to erythropoiesis-stimulatory agents (ESA), which occurs in 30% to 50% of patients,...
Disorders of iron metabolism are commonly seen in onco-hematological clinical practice. Iron-deficie...
Anemia is a prevalent complication in patients with cancer, both at diagnosis and during treatment, ...
Anemia in cancer patients is quite common, with remarkable negative impacts on quality of life and o...
Anemia in cancer patients is quite common, with remarkable negative impacts on quality of life and o...
ABSTRACT Anemia is a frequent complication in cancer patients, both at diagnosis and during treatmen...
AbstractAnemia is a frequent complication in cancer patients, both at diagnosis and during treatment...
Anemia is one of the most common complications of cancer. The severity of anemia depends on the seve...
Background: Chronic diseases reduce the availability of iron for effective erythropoiesis. This revi...
peer reviewedAnaemia and absolute or functional iron deficiency (ID) are common issues among cancer ...
Cancer-related anemia (CRA) continues to be a critical concern despite advancements in oncology trea...
Iron therapy and cancer. Anemia in cancer patients has many etiologies. Iron therapy clearly is indi...
Development of anemia during chemotherapy or chemoradiotherapy of malignancies is a serious adverse ...
Unresponsiveness to erythropoiesis-stimulatory agents (ESA), which occurs in 30% to 50% of patients,...
Unresponsiveness to erythropoiesis-stimulatory agents (ESA), which occurs in 30% to 50% of patients,...
Unresponsiveness to erythropoiesis-stimulatory agents (ESA), which occurs in 30% to 50% of patients,...
Disorders of iron metabolism are commonly seen in onco-hematological clinical practice. Iron-deficie...
Anemia is a prevalent complication in patients with cancer, both at diagnosis and during treatment, ...
Anemia in cancer patients is quite common, with remarkable negative impacts on quality of life and o...
Anemia in cancer patients is quite common, with remarkable negative impacts on quality of life and o...
ABSTRACT Anemia is a frequent complication in cancer patients, both at diagnosis and during treatmen...
AbstractAnemia is a frequent complication in cancer patients, both at diagnosis and during treatment...
Anemia is one of the most common complications of cancer. The severity of anemia depends on the seve...
Background: Chronic diseases reduce the availability of iron for effective erythropoiesis. This revi...
peer reviewedAnaemia and absolute or functional iron deficiency (ID) are common issues among cancer ...
Cancer-related anemia (CRA) continues to be a critical concern despite advancements in oncology trea...
Iron therapy and cancer. Anemia in cancer patients has many etiologies. Iron therapy clearly is indi...
Development of anemia during chemotherapy or chemoradiotherapy of malignancies is a serious adverse ...
Unresponsiveness to erythropoiesis-stimulatory agents (ESA), which occurs in 30% to 50% of patients,...
Unresponsiveness to erythropoiesis-stimulatory agents (ESA), which occurs in 30% to 50% of patients,...
Unresponsiveness to erythropoiesis-stimulatory agents (ESA), which occurs in 30% to 50% of patients,...